A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
Sara Bringhen,Mattia D'Agostino,Laura Paris,Stelvio Ballanti,Norbert Pescosta,Stefano Spada,Sara Pezzatti,Mariella Grasso,Delia Rota-Scalabrini,Luca De Rosa,Vincenzo Pavone,Giulia Gazzera,Sara Aquino,Marco Poggiu,Armando Santoro,Massimo Gentile,Luca Baldini,Maria Teresa Petrucci,Patrizia Tosi,Roberto Marasca,Claudia Cellini,Antonio Palumbo,Patrizia Falco,Roman Hájek,Mario Boccadoro,Alessandra Larocca +25 more
TL;DR: It is shown that fit patientsbenefit from a full-dose triplet regimen, while intermediate-fit and frail patients benefit from gentler regimens, as compared to lenalidomide-dexamethasone.
Journal ArticleDOI
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Reid W. Merryman,Luca Castagna,Laura Giordano,Vincent T. Ho,Paolo Corradini,Anna Guidetti,Beatrice Casadei,David A. Bond,Samantha Jaglowski,Michael A. Spinner,Sally Arai,Robert Lowsky,Gunjan L. Shah,Miguel-Angel Perales,Jean Marc Schiano De Colella,Didier Blaise,Alex F. Herrera,Geoffrey Shouse,Chloé Spilleboudt,Stephen M. Ansell,Yago Nieto,Talha Badar,Mehdi Hamadani,Tatyana Feldman,Lori Dahncke,Anurag K. Singh,Joseph P. McGuirk,Taiga Nishihori,Julio C. Chavez,Anthony Serritella,Justin Kline,Mohamad Mohty,Remy Dulery,Aspasia Stamatoulas,Roch Houot,Guillaume Manson,Marie Pierre Moles-Moreau,Corentin Orvain,Kamal Bouabdallah,Dipenkumar Modi,Radhakrishnan Ramchandren,Lazaros J. Lekakis,Amer Beitinjaneh,Matthew J. Frigault,Yi-Bin Chen,Ryan C. Lynch,Stephen D. Smith,Uttam Rao,Michael Byrne,Jason T. Romancik,Jonathon B. Cohen,Sunita Nathan,Tycel Phillips,Robin Joyce,Maryam Rahimian,Asad Bashey,Hatcher J. Ballard,Jakub Svoboda,Valter Torri,Martina Sollini,Chiara De Philippis,Massimo Magagnoli,Armando Santoro,Philippe Armand,Pier Luigi Zinzani,Carmelo Carlo-Stella +65 more
TL;DR: In this article, a retrospective cohort of 209 patients who underwent allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may be associated with increased toxicity, raising challenging questions about the role, timing, and optimal method of transplantation in this setting.
Journal ArticleDOI
The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer
Ciro Franzese,Paolo Andrea Zucali,Lucia Di Brina,Giuseppe D'Agostino,Pierina Navarria,Davide Franceschini,Armando Santoro,Marta Scorsetti +7 more
TL;DR: Evaluation of the efficacy of Stereotactic Body Radiation Therapy (SBRT) in oligorecurrent and oligoprogressive PC.
Journal ArticleDOI
Dose-escalation of CHOP in non-Hodgkin's lymphoma
Armando Santoro,M. Balzarotti,Carlo Tondini,M. Zanini,Roberto Giardini,F. Latteri,I. Rampinelli,R. Bufalino +7 more
TL;DR: CHOP intensification of approximately 1.8 times that of the standard regimen is feasible and safely administered on an outpatient basis with G-CSF support, and the role of dose-intensity in the outcome of NHL should focus on the comparison of intensified CHOP regimen and standard CHOP or high-dose chemotherapy.
Journal ArticleDOI
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
Sergio Bracarda,Camillo Porta,Corrado Boni,Armando Santoro,Claudia Mucciarini,Antonio Pazzola,Enrico Cortesi,Donatello Gasparro,Roberto Labianca,Francesco Di Costanzo,Alfredo Falcone,Michela Cinquini,Claudia Caserta,Chiara Paglino,Verena De Angelis +14 more
TL;DR: Sorafenib plus frequent low-dose IFN showed good efficacy and tolerability and further investigations should be warranted to identify a possible positioning of this intriguing regimen (6% complete response rate) in the treatment scenario of mRCC.